American Society of Hirudotherapy

De Quervain's Tenosynovitis

Investigational use for stenosing tenosynovitis of the first dorsal extensor compartment; no clinical study of leech therapy for it was identified.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for de Quervain tenosynovitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for de Quervain tenosynovitis, controlled or uncontrolled, was identified. Evidence-based care: thumb spica splinting (the strongest non-operative evidence), NSAIDs, activity modification (avoiding repetitive thumb abduction and ulnar deviation), local corticosteroid injection (the highest-evidence single intervention - cure rate around 80 percent), and (refractory) surgical release of the first dorsal compartment. New onset in postpartum women (mommy thumb) usually responds well to splinting and corticosteroid injection.
Main risks
  • Bleeding from each bite site for 6 to 24 hours after detachment
  • Bruising over the radial wrist for 5 to 10 days
  • Local skin or, rarely, Aeromonas hydrophila infection
  • Allergic reaction to leech saliva (uncommon)
  • RISK if leech is placed over the radial artery or radial sensory nerve
  • Worsening tendon pain from local irritation
  • Delay of thumb spica splinting and corticosteroid injection - which have the strongest evidence
Who should not consider this
  • Patients who have not tried thumb spica splinting for at least 4 to 6 weeks
  • Patients who have not tried corticosteroid injection (the highest-evidence single intervention)
  • Patients with intersection syndrome, CMC arthritis, or radial sensory neuritis mimicking de Quervain
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients with active dermatitis or broken skin over the radial wrist
  • Patients with peripheral vascular disease affecting the wrist
What to ask your clinician
  • Have we confirmed de Quervain tenosynovitis with Finkelstein or Eichhoff testing?
  • Have we ruled out intersection syndrome, CMC arthritis, and radial sensory neuritis?
  • Have I tried a thumb spica splint for at least 4 to 6 weeks?
  • Have I tried corticosteroid injection - the highest-evidence single intervention?
  • Am I a candidate for surgical release of the first dorsal compartment if conservative care fails?
  • Where exactly will the leech be placed - confirm placement avoids the radial artery and radial sensory nerve?
  • What is the Aeromonas-prevention protocol?
When to seek urgent care
  • Sudden severe pain with inability to grip or move the thumb (possible tendon rupture)
  • Numbness, tingling, or hypersensitivity on the dorsal radial hand (possible radial sensory neuritis)
  • Acute swelling, severe pain, or cold pallor of the hand or wrist
  • Bleeding from a bite site lasting more than 24 hours
  • Fever, chills, or spreading redness at the bite site
  • Hives, facial or throat swelling, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for de Quervain tenosynovitis.
  • No controlled trials support efficacy.
  • It does not replace thumb spica splinting and corticosteroid injection - which together have an excellent cure rate.
  • It does not address intersection syndrome, CMC arthritis, or radial sensory neuritis - which need different management.
  • Placement near the radial artery and superficial radial nerve carries vascular and nerve-injury risk if practitioner is not skilled.

Clinical Profile

Category
Musculoskeletal
ICD-10
M65.4
Safety tier
Low

Evidence Summary

De Quervain's tenosynovitis affects the APL and EPB tendons within the first dorsal extensor compartment. Conventional management includes thumb spica splinting, NSAIDs, and corticosteroid injection, which has a high response rate. No clinical study of leech therapy for de Quervain's tenosynovitis (controlled trial, case series or case report) was identified in PubMed, Europe PMC, trial registries or the Russian-language sources searched; use is investigational and mechanistic only. Corticosteroid injection remains the standard second-line therapy, and surgical release is reserved for refractory cases.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Recent local corticosteroid injection (<4 weeks)
  • Active local infection

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.